NCT06933355 - Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

June 1, 2026

Conditions

Kidney Transplantation RecipientsMagnetic Resonance Imaging (MRI)Sodium-Glucose Transporter 2 InhibitorsNon-Diabetic PatientsRandomized Controlled TrialPlacebo Control Design

Interventions

DRUG

JARDIANCE 25mg

"The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients.~4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2.~4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2."

DRUG

Placebo

The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients. 4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2. 4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2.

Trial Locations (1)

5000

Department of Nephrology, Odense University Hospital Kløvervænget 6, Enterance 93, 3. floor, Odense C

All Listed Sponsors

lead

Odense University Hospital

OTHER